United Therapeutics (UTHR)

As of 15 October 2026, short interest in UTHR is 2,457,723 shares, down 342,747 shares over the last month. Over the last 48 readings it ranged from 1,565,617 shares (30 June 2025) to 3,596,948 shares (30 September 2026). At the reported average volume of 958K shares a day that is 2.6 days to cover.

<iframe src="https://xoomar.com/embed/stocks/uthr" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 28 October 2026, the short share of UTHR volume is 47.3%, down 32.6 points over the last five sessions. Over the last 30 readings it ranged from 42.8% (27 October 2026) to 82.3% (5 October 2026). The latest reading is 20.4 points below the 30-session average of 67.8%, on 151K shares reported.

As of 18 September 2026, the fails-to-deliver balance in UTHR is 6,915 shares, up 6,891 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (13 March 2026) to 16,716 shares (3 February 2026).

Insiders at UTHR reported 812 open-market sells worth $333.3M in the last 90 days and no open-market buys. Latest filing: ROTHBLATT MARTINE A (Chairperson & CEO) on 2026-10-27.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

50 Form 144 notices on file for UTHR worth $1.16B at the prices reported; 10 in the last 90 days worth $344.4M. Latest: PAUL MAHON filed on 2026-10-15 to sell 8,300 shares ($4.5M) from 2026-10-15.

2 holders report 5% or more of UTHR in their latest filing, all on Schedule 13G (passive). The largest reported stake is ROTHBLATT MARTINE A at 5.3% of the class (2,333,721 shares), filed 2026-08-14 for an event on 2026-06-30.

8 of the 30 tracked managers held UTHR at their latest 13F, $1.80B in total at quarter-end prices. Renaissance Technologies is the largest at $925.8M (1.3% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 5 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 FY 2026 (quarter ended 2026-06-30) United Therapeutics reported revenue of $783.3M, down 1.9% from the same quarter a year earlier, and net income of $333.0M (7.27 diluted EPS). In FY 2025 it generated $1.56B of operating cash flow and spent $1.00B on buybacks.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-29 from the cover page.